Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

To evaluate the cost-effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) from a payer perspective in the United States.

Source: Value in Health - January 22, 2021 Category: International Medicine & Public Health Authors: Gerasimos Konidaris, Eleanor Paul, Andreas Kuznik, Sam Keeping, Chieh-I Chen, Medha Sasane, Yingxin Xu, Kokuvi Atsou, Dieter Ayers, Emily S. Ruiz, Nikhil I. Khushalani, Shannon Cope Source Type: research